



Dr. Philip Migliore
Research Director
Moran Foundation

7/11/94

Dear Dr. Migliore :

I apologize for the tardiness of my reply concerning the annual progress report for project 64.

We have successfully developed a method for the simultaneous detection of Epstein Barr virus EBER1 RNA and cell surface glycoprotein antigens in human cell lines by flow cytometry. Our results will be presented as an invited oral presentation to the 9th Annual Meeting of the Clinical Cytometry Society in Charleston, SC, on September 12, 1994.

Specifically, we have been able to detect and quantify EBER1-positive B lymphocytes in a mixture of EBV-positive B cells and EBV-negative T cells. B cells are first identified by direct immunofluorescent detection of the CD19 antigen with PE-conjugated anti-CD19 antibody and T cells by direct immunofluorescent detection of the CD3 antigen with PE-conjugated anti-CD3 antibody, followed by indirect immunofluorescent detection of EBER1 RNA using a digoxigenin-labelled oligonucleotide probe complementary to the EBER1 sequence and a FITC-conjugated anti-dig antibody.

Our success now leads us into even more powerful techniques such as in-situ PCR for the detection of low abundance mRNA in cells by flow cytometry. These approaches are leading the way to new powerful techniques for multiparametric analysis of cells by flow cytometry.

Thank you for your support.

Sincerely,

A handwritten signature in black ink, appearing to read 'S. David Hudnall'.

S. David Hudnall, M.D.
Department of Pathology
Baylor College of Medicine